Rani Therapeutics says that it is “one step closer to our goal of making oral biologics a reality for patients with autoimmune diseases,” after initiating a Phase I clinical trial to evaluate the safety and tolerability of its proposed RT-111 orally administered ustekinumab biosimilar.
With topline results from the study expected early in the first quarter of 2024, Rani’s CEO Talat Imran welcomed advancement for RT-111, which is contained in
Key takeaways:
-
Rani Therapeutics has initiated a Phase I clinical trial to evaluate the safety and tolerability of its proposed RT-111 orally administered ustekinumab biosimilar, using Celltrion’s CT-P43 ustekinumab product.
-
The first subject has been administered RT-111 in the single-center, open-label Phase I study, which is being conducted in Australia
